Switch to:

GuruFocus Financial Strength Rank measures how strong a company’s financial situation is. It is based on these factors

1. The debt burden that the company has as measured by its Interest coverage (current year).
2. Debt to revenue ratio. The lower, the better
3. Altman Z-score.

A company ranks high with financial strength is likely to withstand any business slowdowns and recessions.

Financial Strength : 7/10

vs
industry
vs
history
Cash to Debt No Debt
PRAN's Cash to Debt is ranked higher than
84% of the 1248 Companies
in the Global Biotechnology industry.

( Industry Median: 67.35 vs. PRAN: No Debt )
PRAN' s 10-Year Cash to Debt Range
Min: 16.62   Max: No Debt
Current: No Debt

Equity to Asset 0.91
PRAN's Equity to Asset is ranked higher than
93% of the 928 Companies
in the Global Biotechnology industry.

( Industry Median: 0.67 vs. PRAN: 0.91 )
PRAN' s 10-Year Equity to Asset Range
Min: 0.73   Max: 0.99
Current: 0.91

0.73
0.99
F-Score: 3
Z-Score: 12.05
M-Score: -1.58
GuruFocus Profitability Rank ranks how profitable a company is and how likely the company’s business will stay that way. It is based on these factors:

1. Operating Margin
2. Trend of the Operating Margin (5-year average). The company with an uptrend profit margin has a higher rank.
••3. Consistency of the profitability
4. Piotroski F-Score
5. Predictability Rank•

The maximum rank is 10. A rank of 7 or higher means a higher profitability and may stay that way. A rank of 3 or lower indicates that the company has had trouble to make a profit.

Profitability Rank is not directly related to the Financial Strength Rank. But if a company is consistently profitable, its financial strength will be stronger.

Profitability & Growth : 3/10

vs
industry
vs
history
Operating margin (%) -152.91
PRAN's Operating margin (%) is ranked higher than
69% of the 1027 Companies
in the Global Biotechnology industry.

( Industry Median: -78.88 vs. PRAN: -152.91 )
PRAN' s 10-Year Operating margin (%) Range
Min: -4122.44   Max: -152.91
Current: -152.91

-4122.44
-152.91
Net-margin (%) -162.37
PRAN's Net-margin (%) is ranked higher than
68% of the 1027 Companies
in the Global Biotechnology industry.

( Industry Median: -78.05 vs. PRAN: -162.37 )
PRAN' s 10-Year Net-margin (%) Range
Min: -4122.44   Max: -162.37
Current: -162.37

-4122.44
-162.37
ROE (%) -55.96
PRAN's ROE (%) is ranked higher than
66% of the 1143 Companies
in the Global Biotechnology industry.

( Industry Median: -35.75 vs. PRAN: -55.96 )
PRAN' s 10-Year ROE (%) Range
Min: -175.37   Max: -12.84
Current: -55.96

-175.37
-12.84
ROA (%) -48.04
PRAN's ROA (%) is ranked higher than
65% of the 1250 Companies
in the Global Biotechnology industry.

( Industry Median: -28.24 vs. PRAN: -48.04 )
PRAN' s 10-Year ROA (%) Range
Min: -139.79   Max: -7.86
Current: -48.04

-139.79
-7.86
ROC (Joel Greenblatt) (%) -708.62
PRAN's ROC (Joel Greenblatt) (%) is ranked higher than
71% of the 1223 Companies
in the Global Biotechnology industry.

( Industry Median: -438.40 vs. PRAN: -708.62 )
PRAN' s 10-Year ROC (Joel Greenblatt) (%) Range
Min: -21767.52   Max: -516.01
Current: -708.62

-21767.52
-516.01
» PRAN's 10-Y Financials

Financials


Revenue & Net Income
Cash & Debt
Oprt. Cash Flow & Free Cash Flow

» Details

Guru Trades

Q4 2012

PRAN Guru Trades in Q4 2012

Jim Simons 26,500 sh (-37.2%)
» More
Q1 2013

PRAN Guru Trades in Q1 2013

Jim Simons Sold Out
» More
Q3 2013

PRAN Guru Trades in Q3 2013

Jim Simons 163,200 sh (New)
» More
Q4 2013

PRAN Guru Trades in Q4 2013

Jim Simons Sold Out
» More
» Details

Insider Trades

Latest Guru Trades with PRAN

(List those with share number changes of more than 20%, or impact to portfolio more than 0.1%)



No Guru Trades Found!
» Interactive Charts

Peter Lynch Chart ( What is Peter Lynch Charts )

Ratios

vs
industry
vs
history
P/B 2.80
PRAN's P/B is ranked higher than
86% of the 1333 Companies
in the Global Biotechnology industry.

( Industry Median: 6.13 vs. PRAN: 2.80 )
PRAN' s 10-Year P/B Range
Min: 0.44   Max: 31.63
Current: 2.8

0.44
31.63
P/S 11.00
PRAN's P/S is ranked higher than
81% of the 1333 Companies
in the Global Biotechnology industry.

( Industry Median: 28.86 vs. PRAN: 11.00 )
PRAN' s 10-Year P/S Range
Min: 4.83   Max: 126.5
Current: 11

4.83
126.5
EV-to-EBIT -5.45
PRAN's EV-to-EBIT is ranked higher than
70% of the 1333 Companies
in the Global Biotechnology industry.

( Industry Median: 9999.00 vs. PRAN: -5.45 )
PRAN' s 10-Year EV-to-EBIT Range
Min: -53.3   Max: 2.2
Current: -5.45

-53.3
2.2
Current Ratio 10.51
PRAN's Current Ratio is ranked higher than
87% of the 1238 Companies
in the Global Biotechnology industry.

( Industry Median: 4.74 vs. PRAN: 10.51 )
PRAN' s 10-Year Current Ratio Range
Min: 4.11   Max: 11.95
Current: 10.51

4.11
11.95
Quick Ratio 10.51
PRAN's Quick Ratio is ranked higher than
88% of the 1238 Companies
in the Global Biotechnology industry.

( Industry Median: 4.57 vs. PRAN: 10.51 )
PRAN' s 10-Year Quick Ratio Range
Min: 4.11   Max: 11.95
Current: 10.51

4.11
11.95

Valuation & Return

vs
industry
vs
history
Price/Net Cash 3.67
PRAN's Price/Net Cash is ranked higher than
93% of the 1333 Companies
in the Global Biotechnology industry.

( Industry Median: 50.00 vs. PRAN: 3.67 )
PRAN' s 10-Year Price/Net Cash Range
Min: 1.03   Max: 43
Current: 3.67

1.03
43
Price/Net Current Asset Value 3.14
PRAN's Price/Net Current Asset Value is ranked higher than
94% of the 1333 Companies
in the Global Biotechnology industry.

( Industry Median: 29.38 vs. PRAN: 3.14 )
PRAN' s 10-Year Price/Net Current Asset Value Range
Min: 1.03   Max: 43
Current: 3.14

1.03
43
Price/Tangible Book 2.75
PRAN's Price/Tangible Book is ranked higher than
89% of the 1333 Companies
in the Global Biotechnology industry.

( Industry Median: 9.38 vs. PRAN: 2.75 )
PRAN' s 10-Year Price/Tangible Book Range
Min: 0.63   Max: 43
Current: 2.75

0.63
43
Price/Median PS Value 0.58
PRAN's Price/Median PS Value is ranked higher than
93% of the 1333 Companies
in the Global Biotechnology industry.

( Industry Median: 2.20 vs. PRAN: 0.58 )
PRAN' s 10-Year Price/Median PS Value Range
Min: 0.41   Max: 11.32
Current: 0.58

0.41
11.32
Earnings Yield (Greenblatt) -18.30
PRAN's Earnings Yield (Greenblatt) is ranked higher than
61% of the 1218 Companies
in the Global Biotechnology industry.

( Industry Median: -6.30 vs. PRAN: -18.30 )
PRAN' s 10-Year Earnings Yield (Greenblatt) Range
Min: 45.9   Max: 2882.2
Current: -18.3

45.9
2882.2

Analyst Estimate


Warning: Invalid argument supplied for foreach() in /home/gurufocu/public_html/modules/stock/estimate.php on line 31
Jun15 Jun16 Jun17
Revenue(Mil)
EPS($) -0.03 -0.03 -0.03
EPS without NRI($) -0.03 -0.03 -0.03

Business Description

Industry: Biotechnology » Biotechnology
Compare:NVO, AMGN, GILD, BIIB, CELG » details
Traded in other countries:PBT.Australia, PBN.Germany, PBNA.Germany, PRNAF.USA,
Prana Biotechnology Ltd was incorporated on November 11, 1997. The Company is a development stage company at an early stage in the development of its pharmaceutical products. The Company's activities include research into Alzheimer 's disease and other major age-related degenerative disorders.
» More Articles for NAS:PRAN

Headlines

Articles On GuruFocus.com
No related article found.

More From Other Websites
The Lancet Neurology Publishes Prana's Huntington Disease Trial Nov 19 2014
The Lancet Neurology Publishes Prana's Huntington Disease Trial Nov 19 2014
Horizon Pharma's Actimmune Gets Orphan Drug Designation Oct 07 2014
Prana Biotechnology Up on Orphan Drug Status for PBT2 Sep 08 2014
US STOCKS-S&P 500 ends at record as jobs report eases Fed worries Sep 05 2014
US STOCKS-S&P 500 ends at record as jobs report eases Fed worries Sep 05 2014
US STOCKS-Wall St rises as weak payrolls ease Fed worries Sep 05 2014
US STOCKS-Wall St rises as weak payrolls ease Fed worries Sep 05 2014
US STOCKS-Wall St flat following weak payrolls report Sep 05 2014
US STOCKS-Wall St flat following weak payrolls report Sep 05 2014
Huntington’s Disease Orphan Drug Designation Could Rescue Prana Sep 05 2014
US STOCKS-Wall St little changed after weak payrolls report Sep 05 2014
US STOCKS-Wall St little changed after weak payrolls report Sep 05 2014
Why Prana Biotechnology (PRAN) Stock Is Surging Today Sep 05 2014
US STOCKS-Wall St set to dip at open after payrolls report Sep 05 2014
US STOCKS-Wall St set to dip at open after payrolls report Sep 05 2014
US STOCKS-Futures dip before payrolls; on track for weekly fall Sep 05 2014
US STOCKS-Futures dip before payrolls; on track for weekly fall Sep 05 2014
Prana receives FDA Orphan Drug Designation for PBT2 for Huntington Disease Sep 05 2014
3 Biotech Stocks Under $10 in Breakout Territory Aug 29 2014

Personalized Checklist

Checklist has been moved to "Checklist" tab.

Get WordPress Plugins for easy affiliate links on Stock Tickers and Guru Names | Earn affiliate commissions by embedding GuruFocus Charts
GuruFocus Affiliate Program: Earn up to $400 per referral. ( Learn More)
Free 7-day Trial
FEEDBACK